ChinaTrials 18

Event description:

Novotech will participate in ChinaTrials 18 to connect with biotech and pharma leaders advancing cross-border clinical development. Our team will be available to discuss China and APAC development strategy, early-phase planning, regulatory pathways, AI-enabled trial efficiency, clinical quality, and regional collaboration across key global markets.

Novotech will also host a morning seminar focused on integrated early-phase clinical development across China, the US, and Australia. The session will explore global proof-of-concept strategy, cross-regulatory planning, patient-mix design, patient enrollment, Australia’s early-phase value, and practical challenges facing Chinese biotech companies expanding globally.

Novotech Seminar:

Theme: Accelerating Global Proof of Concept (POC): Integrated Early-Phase Clinical Development Strategy across China, US and Australia

Date/Time: October 28, 9:00 a.m.–12:00 p.m.

Seminar Highlights:

• Opening remarks from Andy Liu on Novotech’s global clinical footprint across China, the US, and Australia.
• Cross-regulatory POC planning across China, the US, and Australia.
• Patient-mix strategy for global proof-of-concept success.
• Integrated execution for patient enrollment across China, the US, and Australia.
• Australia’s agile clinical framework for fast, flexible POC generation.
• Panel discussion on regulatory compliance, cross-border project management, early-phase development in Australia, and practical questions for Chinese companies going global.

To connect with Novotech at ChinaTrials 18, please schedule a meeting via the form on this page.